Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 37-41

  Naumann, R Wendel ^a   Sukumvanich, Paniti ^b   Edwards, Robert P ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Intraperitoneal chemotherapy; Ovarian cancer; Society of Gynecologic Oncologists

Indexed keywords

AMIFOSTINE; APREPITANT; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CATHETER INFECTION; CLINICAL PRACTICE; FEMALE; HUMAN; NAUSEA AND VOMITING; NEUROTOXICITY; OUTPATIENT CARE; OVARY CANCER; PERIPHERAL NEUROPATHY; PHYSICIAN ATTITUDE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; COMMUNICATION; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; OVARIAN NEOPLASMS; PHYSICIAN-PATIENT RELATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 67349104381     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.001     Document Type: Article

References (14)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
3. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
4. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
5. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
6. Markman M., Reichman B., Hakes T., Rubin S., Lewis Jr. J.L., Jones W., et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol. Oncol. 50 (1993) 100-104
7. Conte P.F., Bruzzone M., Carnino F., Gadducci A., Algeri R., Bellini A., et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J. Clin. Oncol. 14 (1996) 351-356
8. McGuire W.P., Hoskins W.J., Brady M.F., Homesley H.D., Creasman W.T., Berman M.L., et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13 (1995) 1589-1599
9. Kaye S.B., Paul J., Cassidy J., Lewis C.R., Duncan I.D., Gordon H.K., et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J. Clin. Oncol. 14 (1996) 2113-2119
10. Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol. Oncol. 90 (2003) 637-643
11. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roullet B., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14 (1996) 2101-2112
12. Chin S.N., Pinto V., Rosen B., Oza A., Dodge J., Murphy J., et al. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol. Oncol. 112 (2009) 450-454
13. Hilpert F., Stahle A., Tome O., Burges A., Rossner D., Spathe K., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13 (2005) 797-805
14. Walker J.L. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol. Oncol. 112 (2009) 439-440